Through yeast surface display–based directed evolution, we identified an ICOS-L variant (Y8) carrying two synergistic mutations (Q51P and N57H) that enhanced hICOS affinity by ~ 100-fold relative to wild-type, leading to markedly increased T-cell activation in both in vitro assays and tumor lysis models. The gene discussed is ICOS; the disease is neoplasm.